Home > Medical Research Archives > Issue 149 > Prognostic utility of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for cancer patients with brain metastasis
Published in the Medical Research Archives
May 2020 Issue
Prognostic utility of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for cancer patients with brain metastasis
Published on May 25, 2020
DOI
Abstract
This study aims to determine the utility of the neutrophil-to-lymphocyte-ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) as prognostic markers for brain metastasis (BM). Employing NLR cutoff values at BM diagnosis, 550 patients were divided into groups I-III (I:<3, II: 3–4.49, III: >4.5), and median overall survival (MOS) was calculated (I: 20 months, II: 13.9 months, and III: 7.5 months). Groups divided by a PLR cutoff (I:250, II:≥250 also differed in MOS (13.9 vs. 9.3 months). After multivariable analysis, only NLR was a significant independent predictor of MOS [I vs. II: 1.5 Hazard Ratio (HR); I vs. III: 1.9 HR].
Author info
Bernardo Cacho-díaz, Héctor Spínola-maroño, Javier Prado-peredo, Karen Salmerón-moreno, Laura Mendoza-olivas, Myrna Candelaria-hernández, Ytel Garcilazo-reyes
Author Area
Have an article to submit?
Submission Guidelines
Submit a manuscript
Become a member
